🇺🇸 FDA
Patent

US 9402820

Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors

granted A61KA61K31/19A61K31/355

Quick answer

US patent 9402820 (Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/19, A61K31/355, A61K45/06